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Introduction
The actin cytoskeleton is a highly dynamic structure that is
remodelled in response to a variety of signals. It plays essential
roles in the regulation of numerous cellular processes, such as
cell migration, wound repair and vesicle exocytosis (Sun et al.,
1999; Gasman et al., 2004).
In pancreatic -cells, the main role of which is to control
glucose homeostasis, insulin-containing granules undergo
tightly regulated exocytosis as a response to extrinsic stimuli
(such as glucose) that lead to an elevation in cytosolic calcium
(Easom, 2000; Ashcroft et al., 1994), in a process that
shares many similarities with the calcium-regulated release
of neurotransmitters and hormones by neurons and
neuroendocrine cells (Bader et al., 2004). A number of
previous studies support the idea of actin cytoskeleton
reorganisation being coupled to calcium-regulated exocytosis,
but the precise role of actin has not been elucidated (Aunis and
Bader, 1988; Bader et al., 2004; Eitzen, 2003). F-actin, which
in pancreatic -cells is organised as a dense web beneath
the plasma membrane (Orci et al., 1972), is transiently
depolymerised after glucose stimulation of insulin secretion
(Thurmond et al., 2003). This secretion is facilitated by the
disruption of the F-actin network with cytochalasin B (Jijakli
et al., 2002), latrunculin B (Thurmond et al., 2003) or
Clostridium botulinum C2 toxin (Li et al., 1994) in insulin-
secreting cell lines, suggesting that F-actin limits the access of
insulin granules to the plasma membrane. By contrast, actin
filament disruption with C2 toxin inhibited insulin secretion in
poorly granulated HIT-T15 cells (Li et al., 1994), indicating an
alternative role for F-actin in the recruitment of secretory
granules to the releasable pool. Recent reports have underlined
a possible role for the Rho GTPases Cdc42 (Nevins and
Thurmond, 2003; Kowluru et al., 1997) and Rac (Li et al.,
2004; Kowluru et al., 1997) in cortical F-actin reorganisation
during regulated insulin secretion, but the exact mechanism of
action, as well as the key proteins implicated in this important
process, remain unknown.
In this study, two different sublines derived from the parental
mouse pancreatic -cell line MIN6, designated B1 and C3,
which have been previously characterised as having similar
insulin content but different secretory properties [with B1 but
not C3 cells responding to glucose in a concentration-
dependent manner (Lilla et al., 2003)], have been employed
with a view to identifying novel genes and mechanisms
involved in the regulation of -cell actin organisation and
insulin secretion. First, we establish that these two sublines
have very different actin cytoskeleton organisation and
remodelling properties. We further employ the comparison of
B1 and C3 cells to provide the first evidence of the involvement
of the Ca2+-dependent actin remodelling protein gelsolin in
We have previously isolated two MIN6 -cell sublines, B1,
highly responsive to glucose-stimulated insulin secretion,
and C3, markedly refractory (Lilla, V., Webb, G.,
Rickenbach, K., Maturana, A., Steiner, D. F., Halban, P. A.
and Irminger, J. C. (2003) Endocrinology 144, 1368-1379).
We now demonstrate that C3 cells have substantially
increased amounts of F-actin stress fibres whereas B1 cells
have shorter cortical F-actin. Consistent with these data,
B1 cells display glucose-dependent actin remodelling
whereas, in C3 cells, F-actin is refractory to this
secretagogue. Furthermore, F-actin depolymerisation with
latrunculin B restores glucose-stimulated insulin secretion
in C3 cells. In parallel, glucose-stimulated ERK1/2
activation is greater in B1 than in C3 cells, and is
potentiated in both sublines following F-actin
depolymerisation. Glucose-activated phosphoERK1/2
accumulates at actin filament tips adjacent to the plasma
membrane, indicating that these are the main sites of action
for this kinase during insulin secretion. In addition, B1 cell
expression of the calcium-dependent F-actin severing
protein gelsolin is >100-fold higher than that of C3 cells.
Knock-down of gelsolin reduced glucose-stimulated insulin
secretion, whereas gelsolin over-expression potentiated
secretion from B1 cells. Gelsolin localised along
depolymerised actin fibres after glucose stimulation. Taken
together, these data demonstrate that F-actin
reorganization prior to insulin secretion requires gelsolin
and plays a role in the glucose-dependent MAPK signal
transduction that regulates -cell insulin secretion.
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2157Actin remodelling and insulin secretion
glucose-regulated insulin secretion, as well as to unveil a link
between F-actin remodelling and glucose-dependent activation
and subcellular localisation of the mitogen-activated protein
kinase (MAPK) signalling cascade member extracellular
signal-regulated kinase 1/2 (ERK1/2), two of the processes
implicated in the potentiation of regulated insulin secretion in
the -cell. 
Results
Differences in actin cytoskeleton organisation and
remodelling between MIN6 sublines B1 and C3
In order to establish the validity of the B1 versus C3 cell model
for the study of the mechanisms implicated in -cell actin
reorganisation and its importance in regulated insulin
secretion, we determined whether there was any difference in
the actin cytoskeleton organisation and remodelling between
the well-regulated insulin-secreting B1 subline and the
dysregulated glucose-insensitive C3 subline. Phalloidin
staining of cell monolayers from these two sublines showed
marked differences in their F-actin cytoskeleton properties
(Fig. 1). In basal conditions (0 mM glucose), B1 cells display
shorter more curved cortical actin filaments compared to C3
cells, the latter being rich in long stress fibres underlying the
cell membrane. As shown in Fig. 1A, and as previously
reported for MIN6 cells using these same conditions
(Thurmond et al., 2003), the actin cytoskeleton of B1 cells
partially depolymerises shortly after stimulation with 20 mM
glucose, whereas the actin cytoskeleton of C3 cells remains
unchanged. Similar results were obtained under more
physiologically relevant basal conditions (2.8 mM glucose)
followed by stimulation at 16.7 mM glucose (Fig. 1B).
The partial depolymerisation of the F-actin cytoskeleton did
not take place when the cAMP phosphodiesterase inhibitor
IBMX, which increases intracellular cAMP levels and
potentiates insulin secretion (Siegel et al., 1980), was used
instead of glucose as the stimulatory agent (Fig. 1C).
Actin depolymerisation by latrunculin B treatment
potentiates glucose-regulated insulin secretion in the
MIN6 B1 subline and restores regulated insulin
secretion in the MIN6 C3 subline
Treatment with the actin depolymerising agent latrunculin B
has been previously demonstrated to potentiate glucose-
stimulated insulin secretion in MIN6 cells (Thurmond et al.,
2003). In view of the abnormal distribution and glucose-
dependent actin remodelling properties of the secretion-
defective C3 subline, we explored the possible effects of
latrunculin B on the glucose-dependent insulin secretion of
this as well as of the glucose-responsive B1 subline. The
effectiveness of latrunculin B treatment on the actin
depolymerisation of B1 and C3 cells was assessed by
phalloidin staining of cell samples pre-treated with the drug (or
with DMSO as a negative control) for 2 hours at basal
conditions followed by 10 minutes stimulation with 20 mM
glucose (Fig. 2A). Untreated B1 cells display a partial
depolymerisation of cortical actin similar to that shown in Fig.
1A, whereas latrunculin B pre-treated B1 cells had a disrupted
actin cytoskeleton, with F-actin extensively fragmented and
scattered throughout the cell. In the case of the C3 subline,
untreated cells retained a stress fibre-rich actin cytoskeleton
after glucose stimulation, but latrunculin B pre-treated cells
displayed a similar level of actin disruption to latrunculin B-
treated B1 cells.
Pre-treatment of B1 cells with latrunculin B resulted in an
increase of 3.7-fold (from 15.7±1.9 to 58.1±8.0 stimulated
versus basal fold increase) in glucose-stimulated insulin
secretion without any significant impact on basal secretion
(Fig. 2B, top panels). This increase was sustained throughout
the 1 hour stimulatory period (Fig. 2C, left panel). As shown
previously (Lilla et al., 2003), the C3 subline did not display
any increase in insulin secretion in response to glucose (fold-
stimulation 1). However, there was an increase of 10.9-fold
(from 0.92±0.06 to 9.985±0.62 stimulated vs basal fold
increase) in the secretory response to glucose after latrunculin
B-induced actin depolymerisation in this subline (Fig. 2B,
bottom panels, and Fig. 2C, right panel), with a 54.5-fold
Fig. 1. Confocal microscopy images showing the differences in the
organisation and dynamic properties of the actin cytoskeleton in B1
and C3 cells. Response of cells to (A)10 minutes stimulation with 20
mM glucose after 0 mM glucose; (B) 16.7 mM after 2.8 mM
glucose; and (C) 1 mM IBMX without glucose. F-actin was stained
with phalloidin. Bars, 10 m.
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increase of stimulated insulin secretion
and a lower but significant impact
(fivefold increase) on basal secretion. The
increase in secretion measured after
latrunculin B pre-treatment in both B1
and C3 sublines was not accompanied
by significant differences in the total
(secreted + intracellular) insulin content
of either subline as compared to control
DMSO-treated cells (Fig. 2D).
Differential expression of the F-actin
remodelling protein gelsolin between
MIN6 B1 and C3 cells
B1 and C3 cells have been subjected
in the past to a thorough analysis of
differentially expressed genes by high
density (Affymetrix) oligonucleotide
microarrays (Lilla et al., 2003). In this
study, the candidate Ca2+-dependent
actin remodelling protein gelsolin was
identified as being grossly over-expressed
in B1 compared to C3 cells. In order to
verify the microarray results, the level of
gelsolin mRNA was determined in both
B1 and C3 cells by real-time RT-PCR.
The results obtained were comparable to
the microarray analysis and indicated an
increase of more than 100-fold in the
level of gelsolin mRNA in B1 compared
with C3 cells (Table 1). This increase in
gelsolin expression was subsequently
confirmed at the protein level by western
blot analysis of protein samples from
both sublines, and also from sorted
primary mouse and rat pancreatic -cells
for comparison (Fig. 3A). Gelsolin
protein levels were clearly increased in
B1 compared to C3 cells, with mouse
primary -cells displaying a similar level
of gelsolin to B1 cells, and rat primary
-cells exhibiting an intermediate level
of expression, but clearly higher than
that of the defective C3 subline.
Immunofluorescence analysis of gelsolin
subcellular localisation in B1 cells
showed that the protein partially co-
localises with cortical actin beneath the
plasma membrane (Fig. 3B).
RNA interference analysis indicates
that gelsolin participates in
extracellular Ca2+-dependent
glucose-stimulated insulin secretion
in MIN6 B1 cells
In view of the difference in the level of
expression of gelsolin between the
glucose-responsive insulin-secreting B1
and the glucose-insensitive C3 sublines,
and the documented role of this protein
in dynamic alterations of the actin
Journal of Cell Science 119 (10)
Fig. 2. Effect of actin depolymerisation on the secretory response to glucose in B1 and C3
cells. (A) Latrunculin B-dependent depolymerisation of F-actin in B1 and C3 cells. Bar, 20
m. (B) Stimulatory effect of actin depolymerisation by 10 M latrunculin B on glucose-
dependent insulin secretion in B1 and C3 cells. Left panels: basal (0 mM glucose for 1
hour) and stimulated (20 mM glucose for 1 hour) insulin secretion as a percentage of cell
content; rights panels: fold-stimulation (*P<10–4). (C) Time-course of insulin secretion (20
mM glucose) by B1 and C3 cells with or without 10 M latrunculin B. (D) Insulin content
in B1 and C3 sublines with or without 10 M latrunculin B treatment. Data in all cases are
mean ± s.e.m. of three independent experiments.
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2159Actin remodelling and insulin secretion
cytoskeleton (Sun et al., 1999; Kwiatkowski, 1999), we
decided to analyse the role of gelsolin in regulated insulin
secretion. For this purpose, we employed the RNA
interference technique to knock-down gelsolin in B1 cells. In
order to assess the efficacy of gelsolin down-regulation, B1
cells were transiently transfected with plasmids expressing
two different short hairpin RNA (shRNA) sequences specific
for mouse gelsolin mRNA and the fluorescent protein GFP as
a marker for transfected cells. As a negative control, cells
were transfected with the same type of plasmid expressing
a non-mammalian unrelated shRNA. Three days after
transfection, cells were collected and analysed by
fluorescence-activated cell sorting in which only the GFP-
positive shRNA-expressing cells were collected. Gelsolin
protein levels were later determined in sorted cell samples by
western blot analysis, as shown in Fig. 4A for the most
effective of the two gelsolin shRNAs analysed. This construct
knocked down gelsolin in B1 cells to very low levels when
compared to negative control shRNA-expressing cells, and
was therefore subsequently used to examine the impact of
gelsolin on insulin secretion.
To determine the involvement of gelsolin in glucose-
stimulated insulin secretion, B1 cells were co-transfected with
the plasmid expressing shRNA for gelsolin and a human
growth hormone (hGH)-expressing vector. Human growth
hormone was used as a surrogate marker for insulin secretion
from the subpopulation of transfected cells, as this hormone
is stored (Schweitzer and Kelly, 1985) and co-secreted with
insulin in pancreatic -cells (Holz et al., 1994; Wang et al.,
1997; Iezzi et al., 1999). B1 cells transfected with the control
non-specific shRNA plasmid displayed a fivefold increase in
growth hormone secretion after raising the level of glucose in
the incubation medium from 2.8 mM to 16.7 mM for 1 hour,
whereas B1 cells transfected with the gelsolin-specific
shRNA-expressing vector reached only a 3.2-fold increase in
growth hormone secretion after glucose stimulation (Fig. 4B).
Gelsolin-depleted B1 cells therefore lost a statistically
significant 36% of their secretory response to glucose
compared to control cells.
To characterise further this loss of secretion in gelsolin-
depleted cells, growth hormone secretion experiments were
repeated using 1 mM IBMX alone (Fig. 4C, top panels) or 1
mM IBMX supplemented with 16.7 mM glucose (Fig. 4C,
bottom panels) as secretagogues. We could not measure any
significant decrease in growth hormone secretion from
gelsolin-depleted cells compared with control cells in any of
these instances, indicating a glucose-specific role for gelsolin
in insulin secretion.
We next determined whether the stimulatory effect of
latrunculin B treatment on glucose-induced secretion in B1
cells was counteracted by gelsolin depletion. For this purpose,
similar hGH secretion experiments were performed on control
and gelsolin shRNA-transfected B1 cells after 2 hours
latrunculin B pre-treatment (Fig. 4D). Under these conditions,
and contrary to the results obtained for the secretion of insulin
(Fig. 2B), latrunculin B pre-treatment caused an increase in
basal growth hormone secretion in both control and gelsolin-
depleted cells (compare Fig. 2B and Fig. 4D). We could
nevertheless measure a 31% reduction in the level of stimulated
growth hormone secretion in gelsolin-depleted cells as
compared to the control, indicating that gelsolin depletion can
partially counteract the effect of latrunculin B on stimulated
growth hormone secretion in B1 cells.
Effect of over-expression of gelsolin in the
glucose-dependent actin remodelling properties
and the secretory response of MIN6 B1 and C3
cells
To examine further the role of gelsolin in short-term
actin remodelling and its link to insulin secretion, we
transfected both B1 and C3 cells with a plasmid
expressing mouse gelsolin cDNA fused to an HA
tag (pcDNA3.1+hygro-HA-mGsn; a gift from H.
Fujita, National Cardiovascular Center Research
Institute, Osaka, Japan), or with the same plasmid in
which the HA-gelsolin construct had been excised for
control purposes (pcDNA3.1+hygro). In Fig. 5A, the
level of gelsolin in untransfected (wt) cells is
compared to that in cells transfected with the
control or the HA-gelsolin expression plasmids for
both B1 and C3 sublines. These results show that
transfection with the HA-gelsolin expression
plasmid results in an over-expression of gelsolin in
B1 cells and a restoration of gelsolin expression in
C3 cells.
Both B1 and C3 sublines were subsequently
transfected with the HA-gelsolin expression plasmid,
Table 1. Differences in gelsolin mRNA levels in MIN6 B1
and C3 cells 
Ratio B1/C3
Mean ± s.e.m.
Microarray 145.7 48.9
Real time RT-PCR 115.8 31.7
Data are the mean ± s.e.m. of three independent experiments.
Results for microarray analysis are taken from Lilla et al. (Lilla et al.,
2003).
Fig. 3. (A) Western blot analysis of the differences in the level of gelsolin in
B1, C3, mouse and rat primary pancreatic -cells. (B) Subcellular
localisation of gelsolin (green) and F-actin (red) in B1 cells. No
immunoreactivity was observed using control rabbit IgG (not shown). Bar,
10 m.
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and the subcellular localisation of HA-gelsolin
was analysed in conjunction with the F-actin
cytoskeleton by confocal immunofluorescence at
both basal (0 mM glucose) and stimulated (20
mM glucose) conditions (Fig. 5B). In B1 cells
under basal conditions (Fig. 5B, top panels, 0
mM glucose), the level of actin polymerisation
in transfected HA-tag-positive cells is
comparable to that of untransfected cells on the
same dish. Upon glucose stimulation, HA-
gelsolin relocates specifically to actin filaments
and the extent of glucose-induced actin fibre
depolymerisation appears to be increased in
transfected cells as compared to untransfected
cells on the same dish (Fig. 5B, top panels, 20
mM glucose). By contrast, in C3 cells HA-
gelsolin is clearly localised along the entire
length of actin filaments even in basal conditions
(Fig. 5B, bottom panels, 0 mM glucose), and
depolymerisation of these actin filaments is
increased in transfected cells in both basal and
stimulated conditions as compared to
untransfected cells on the same dish (Fig. 5B,
bottom panels, 0 and 20 mM glucose).
We then analysed the level of growth hormone
secretion in B1 and C3 cells that had been
co-transfected with either the HA-gelsolin
expression plasmid or the control empty
plasmid and an hGH-expressing vector. For B1
cells, we measured an increase of 42% in
stimulated growth hormone secretion in
gelsolin over-expressing cells as compared to
the control without any significant effect on
basal secretion (Fig. 5C). However, we could not
measure any significant increase of stimulated
growth hormone secretion between HA-gelsolin
and control C3 transfected cells (data not
shown). This seemingly contradictory result might be
explained in combination with the immunofluorescence data
in Fig. 5B as resulting from dysregulation of gelsolin action
Journal of Cell Science 119 (10)
on the defective C3 subline, where gelsolin appears to
promote actin depolymerisation even in the absence of
glucose. 
Fig. 4. Analysis of the role of gelsolin in insulin
secretion by RNAi in B1 cells. (A) Western blot
showing the effect of RNAi treatment on gelsolin
protein levels in B1 cells. GFP-positive B1 cells
transfected with either pSUPER-GFP gelsolin RNAi
or pSUPER-GFP control plasmids were selected by
FACS and used for immunoblotting. Equal loading
was confirmed with an anti-actin antibody. (B,C) B1
cells were co-transfected with pSUPER-gelsolin RNAi
or pSUPER-control RNAi plasmids and an hGH-
expressing vector, and growth hormone secretion was
measured after stimulation with 16.7 mM glucose (B),
1 mM IBMX (C, top panels), or a combination of 16.7
mM glucose and 1 mM IBMX (C, bottom panels).
Data are mean ± s.e.m. of five independent
experiments (B, right panel: *P<410–4). (D) Growth
hormone secretion in B1 cells co-transfected with
pSUPER-gelsolin RNAi or pSUPER-control RNAi
plasmids and an hGH-expressing vector after a 2 hour
pre-incubation with 10 M latrunculin B. Data are
mean ± s.e.m. of two independent experiments.
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The actin cytoskeleton depolymerisation state is linked
to the glucose-dependent activation of the MAPK
signalling cascade during stimulation of insulin secretion
in MIN6 cells
In order to deepen our understanding of the role of short-term
actin remodelling in glucose-stimulated insulin secretion, and
prompted by previous reports showing a link between the actin
cytoskeleton and the activation of the MAPK pathway by
insulin in insulin-responsive muscle cells (Tsakiridis et al.,
1998), we examined whether there was a connection between
the glucose-induced actin remodelling and the activation of the
MAPK pathway in -cells. Specifically, we investigated if
there were differences in the glucose-dependent activation of
ERK1/2 and its subcellular localisation in B1 compared with
C3 cells, and if these possible differences were related to the
distinct actin remodelling characteristics identified in the two
MIN6 sublines.
To confirm that ERK1/2 played a role in insulin secretion in
B1 cells, the selective pharmacological inhibitor PD98059 was
used to inhibit MEK1/2, the upstream ERK1/2 kinase (Pang
et al., 1995). To verify that PD98059
treatment abolished ERK1/2 activation by
glucose, B1 cells were pre-incubated for 2
hours with PD98059 (or DMSO as a
negative control), and stimulated with 10
mM glucose. Cells were collected after 5-,
15- and 30-minute incubations and ERK1/2
activation was analysed by western blot
using an antibody specific for the
phosphorylated active form of the protein
(Fig. 6A). Both ERK isoforms 1 and 2 were
phosphorylated following incubation at 10
mM glucose (see also Fig. 7A), and this
phosphorylation was blocked by pre-
treatment with PD98059.
We next analysed the effect of PD98059
pre-treatment on insulin secretion from B1
cells after stimulation with 10 mM glucose
for the same three time periods as above
(Fig. 6B). There was a 60% decrease in
the fold-stimulation of insulin secretion
(stimulated versus basal condition) in
PD98059-treated cells when compared to
control DMSO-treated cells after 5 minutes
glucose stimulation (top panel). However,
after 15 minutes in glucose, this difference
Fig. 5. Analysis of the role of gelsolin in actin
depolymerisation and insulin secretion by
exogenous expression of an HA-tagged gelsolin
cDNA construct in B1 and C3 cells.
(A) Western blot showing the effect of
exogenous expression of HA-gelsolin in B1 and
C3 cells on the total level of gelsolin.
Exogenous HA-gelsolin was specifically
detected with an anti-HA-tag antibody (10 g
total protein/lane). (B) Immunofluorescence
analysis of the subcellular localisation of HA-
gelsolin (green) and the actin cytoskeleton (red)
on B1 (top panels) and C3 cells (bottom panels)
with or without 20 mM glucose stimulation.
Nuclei (blue) were stained with DRAQ5TM. For
glucose-stimulated B1 cells, two examples of
HA-gelsolin-expressing cells are given and the
actin (red) signal is boosted in the higher
magnification image (zoom) to facilitate
visualisation of actin/gelsolin co-localisation.
Bars, 10 m (unless stated otherwise).
(C) Growth hormone secretion by B1 cells co-
transfected with an HA-gelsolin expression
plasmid or with a control empty plasmid. Data
are mean ± s.e.m. of three replicates of a single
experiment.
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had been reduced to 30% (middle panel), and no
significant difference was observed after 30
minutes glucose stimulation. These results show
that ERK1/2 activity contributes to the short-term
but not to the long-term glucose-induced insulin
secretion of B1 cells.
Once it was established that ERK1/2 activation
has an important role in the short-term insulin
secretion of B1 cells, we compared the levels of
activation of ERK1/2 after short-term (5 minutes)
glucose exposure in B1 and C3 cells, and we also
investigated the effect of actin depolymerisation
by latrunculin B pre-treatment on the level of
activation of ERK1/2 in these two sublines. For
these purposes, B1 and C3 cells were pre-treated
with either latrunculin B or DMSO (as a negative
control) in the absence of glucose for 2 hours, and
stimulated for 5 minutes with 20 mM glucose, and
the levels of ERK1/2 phosphorylation were
subsequently determined by western blotting (Fig.
7A). Both B1 and C3 cells showed no activation
of ERK1/2 in the absence of glucose for either the
control or the latrunculin B-treated cell samples,
this being an indication of the absence of
secondary effects of the latrunculin B pre-
treatment per se on ERK1/2 phosphorylation.
After glucose stimulation, ERK1/2 was
phosphorylated in both B1 and C3 cells, but the
level of phosphorylation of the ERK2 isoform was
reduced in C3 as compared to B1 cells (2.15-fold
increase B1/C3), indicating a partial defect in
MAPK activation by glucose in the secretion-
impaired C3 cell line. After actin depolymerisation
by latrunculin B pre-treatment, the level of
glucose-induced ERK1/2 phosphorylation
increased in both B1 and C3 cells, this increase
being greater for the C3 cell line (7.5-fold increase
with or without latrunculin B pre-treatment).
Activated phosphoERK1/2 accumulates at
the tips of actin filaments in the vicinity of the
plasma membrane upon stimulation with
glucose
The short time frame associated with the activity
of ERK1/2 on insulin secretion precludes a classic
mechanism of action in which this kinase would
translocate to the nucleus in order to regulate gene
transcription. Instead, a mechanism in which
phosphoERK1/2 is involved in the activation of
specific cytoplasmic targets that would potentiate
insulin secretion is more readily explainable. In
order to gain more insight into this question,
we analysed the subcellular localisation of
phosphoERK1/2 in conjunction with the F-actin
cytoskeleton by confocal immunofluorescence at
basal (0 mM glucose) and stimulated (20 mM
glucose) conditions in both B1 and C3 cells (Fig.
7B). As expected, we did not detect any signal for
the phosphorylated form of ERK1/2 in the absence
of glucose in either B1 or C3 cells. Upon glucose
stimulation, phosphoERK1/2 localised throughout
Journal of Cell Science 119 (10)
Fig. 6. ERK1/2 activity contributes to the short-term glucose-induced insulin
secretion in B1 cells. (A) Western blot analysis of the inhibitory effect of
PD98059 on the activation (by phosphorylation) of ERK1/2 after 10 mM glucose
stimulation in B1 cells. (B) Insulin secretion by B1 cells treated with PD98059 at
three different time points. After 5 minutes glucose stimulation (top), B1 cells
display a 60% decrease in their secretory response as compared to control
DMSO-treated cells (*P<0.05). However, after 15 minutes stimulation (middle),
the decrease in insulin secretion is reduced to 30% (**P<0.02), and is not present
after 30 minutes glucose stimulation (bottom). Data in all cases are mean ± s.e.m.
for basal and stimulated % insulin secretion (left panels) and secretion fold-
stimulation (right panels) of three replicates of a single experiment. Stimulation
conditions of 0 to 10 mM glucose were used to facilitate direct comparison with
previously published work showing the effect of glucose-dependent ERK1/2
activation on insulin secretion (Longuet et al., 2005).
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the cytoplasm, displaying a punctate pattern in both sublines.
Upon closer examination, we detected an accumulation of
the phosphoERK1/2-specific signal at the tips of remodelled
actin filaments at sites adjacent to the plasma membrane in B1
cells stimulated at both 20 mM glucose and at the more
physiological concentration of 16.7 mM glucose (Fig. 7C).
This subcellular localisation of phosphoERK1/2 at the tips of
actin fibres was also present but substantially diminished in C3
cells (Fig. 7B, bottom panels).  
We next determined whether the localisation of activated
phosphoERK1/2 at the tips of actin filaments could be
responsible for the process of actin remodelling itself, rather
than being a downstream consequence of this remodelling
process that would be further involved in the phosphorylation
Fig. 7. (A) Western blot analysis showing the differences in short-term glucose-induced ERK1/2 activation between B1 and C3 sublines and the
stimulatory effect of latrunculin B pre-treatment on the short-term phosphorylation of ERK1/2. (B) Immunofluorescence analysis of the
subcellular localisation of activated phosphoERK1/2 (green) and the actin cytoskeleton (red) on B1 (top panels) and C3 cells (bottom panels)
before and after 5 minutes stimulation with 20 mM glucose. Nuclei (blue) were stained with DRAQ5TM. No immunoreactivity was observed
using control rabbit IgG (not shown). Bars, 10 m. (C) PhosphoERK1/2 accumulates at the tips of actin fibres in the vicinity of the plasma
membrane (white arrows) after 20 mM glucose (left) and 16.7 mM glucose (right) stimulation in B1 cells. Bar, 10 m. (D) Inhibition of
ERK1/2 activation by PD98059 has no effect on the actin cytoskeleton remodelling properties of B1 or C3 cells as shown by confocal analysis
of phalloidin-labelled cell samples + PD98059 before and after 5 minutes glucose stimulation. Bars, 10 m.
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of specific targets implicated in the potentiation of insulin
secretion. For this purpose, we pre-incubated both B1 and C3
cells with the ERK1/2 inhibitor PD98059 prior to glucose
stimulation and analysed the effects on actin cytoskeleton
reorganisation by immunofluorescence (Fig. 7D). Under these
experimental conditions, we could not detect any differences
in the actin cytoskeleton remodelling properties of these two
sublines as compared with untreated cells (Fig. 7D, compare
with Fig. 1A,B).
Taken together, these results indicate that glucose-induced
actin remodelling contributes towards the initiation of a rapid-
response signalling pathway that leads to the short-term
activation of ERK1/2, this activation either occurring at the tips
of remodelled actin filaments or promoting the rapid re-
localisation of phosphoERK1/2 to these actin filament tips,
where it could function in the potentiation of the rapid glucose-
dependent insulin secretory response in MIN6 -cells, most
probably by phosphorylating specific downstream targets at
these precise cell sites in the vicinity of the plasma membrane
and in close contact with the actin cytoskeleton.
Discussion
The dynamic control of actin distribution during regulated
secretion is a complex process in which a number of regulatory
proteins including the small GTPases cdc42 (Nevins and
Thurmond, 2003) and Rac1 (Li et al., 2004), structural proteins
such as fodrin (Nakano et al., 2001) and motor proteins such
as the myosins (Wilson et al., 2001; Rudolf et al., 2003) have
already been identified, even if the precise mechanism of action
remains to be established.
In the present study we have characterised the differences in
actin cytoskeleton organisation and remodelling between two
-cell sublines generated from mouse MIN6 cells with a view
to identifying novel genes involved in regulated insulin
secretion. Importantly for the present study, differences in
secretory pattern between B1 and C3 cells were not attributed
to any metabolic defect. Rather, C3 cells, which fail to respond
to glucose or most other fuel and non-fuel secretagogues,
appeared to have a lesion late in the exocytotic pathway (Lilla
et al., 2003).
The actin cytoskeleton of the glucose-responsive B1 subline
was found to be a dynamic structure resembling that of the
parental MIN6 cell line in its capacity to partially depolymerise
in response to glucose (Thurmond et al., 2003; Nevins and
Thurmond, 2003), whereas the glucose-insensitive C3 subline
had a rigid cytoskeleton, with an abundance of stress fibres in
the subplasmalemmal region that were not remodelled after
glucose stimulation.
Transient depolymerisation of the actin network in response
to stimuli in pancreatic -cells and other secretory cell types
has often been correlated with their capacity for stimulated
secretion (Thurmond et al., 2003; Koffer et al., 1990; Rose et
al., 2001; Wilson et al., 2001). In agreement with this, and as
previously shown for the parental MIN6 cell line (Thurmond
et al., 2003), treatment with the actin depolymerising drug
latrunculin B potentiated insulin secretion in B1 cells.
Moreover, the normally secretory-impaired C3 cells became
glucose-responsive under the same conditions of latrunculin B
treatment, demonstrating a direct link between the actin
polymerisation state and the capacity for regulated insulin
secretion in these sublines.
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The differences in actin cytoskeleton morphology and
remodelling between the B1 and C3 sublines and the
restoration of regulated insulin secretion after actin
depolymerisation in C3 cells make the comparison between
these two subclones an attractive model for the study of the
mechanism of glucose-induced actin remodelling and its
importance for insulin secretion.
We employed this model to identify the protein gelsolin as
a candidate for glucose-induced actin remodelling in MIN6
cells. Gelsolin is well known for its involvement in dynamic
changes of the actin cytoskeleton in response to changes in
intracellular Ca2+ levels (Sun et al., 1999; Kwiatkowski, 1999),
and was previously identified by microarray analysis as being
over-expressed in B1 compared with C3 cells (Lilla et al.,
2003). In confirmation of this earlier observation, both gelsolin
mRNA and protein were found to be expressed at much higher
levels in B1 than in C3 cells, and the level of expression of
gelsolin in primary mouse -cells was comparable to that
found in B1 cells. In B1 cells, in common with other secretory
cell types such as chromaffin cells (Aunis and Bader, 1988),
gelsolin was found to localise to the subplasmalemmal area of
the actin cytoskeleton. The presence of pronounced actin stress
fibres in the secretion-impaired C3 cells might be related to the
loss of gelsolin expression in this subline, as this same
phenotype has been previously reported in fibroblasts from
gelsolin null mice (Witke et al., 1995).
When gelsolin was knocked down by RNA interference in
B1 cells, there was a significant decrease in glucose-stimulated
secretion. Gelsolin knock-down was also able to partially
counteract the stimulation of secretion after actin
depolymerisation by latrunculin B, showing a close
relationship between the actin polymerisation level and the
level of secretion in B1 cells. Conversely, gelsolin knock-down
had little or no effect on the secretory response induced by
elevation of cAMP by IBMX. This observation, which
correlates with the absence of actin depolymerisation after
IBMX treatment, is most probably explained by the divergent
mechanisms of stimulation of insulin secretion between
glucose and cAMP (Yajima et al., 1999; Dyachok and Gylfe,
2004). By contrast, gelsolin over-expression resulted in a
significant increase in stimulated hGH secretion in transfected
B1 cells. This result, together with the loss of secretion after
gelsolin knock-down, demonstrates a link between the level of
this protein and the extent of regulated secretion in the B1
subline.
The decrease in glucose-dependent hGH secretion observed
after gelsolin knock-down in B1 cells was partial, whereas
regulated secretion was totally impaired in C3 cells. Several
factors may contribute to this outcome, such as the partial
efficacy of the co-transfection method in selecting knocked-
down cells or the residual level of gelsolin left after the shRNA
treatment. In addition, other proteins involved in the process of
actin remodelling could be over-expressed or alternative
pathways switched on to guarantee partial functionality of the
secretion process. In this context, it is worth noting that C3
cells have extensive differences in their mRNA expression
profile compared to B1 cells, with more than 200 genes either
over- or under-expressed an average of twofold or more
between these two sublines (Lilla et al., 2003), indicating that
C3 cells suffer from an extensive number of defects, the
combination of which most probably leads to the altered
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phenotype. The above-mentioned results correlate well with
the fact that actin depolymerisation by latrunculin B treatment
in B1 cells results in a 58-fold increase in insulin secretion,
whereas the same treatment in C3 cells results only in a tenfold
increase.
The accumulated defects harboured in C3 cells might
explain not only the partial secretory decrease observed in B1
cells after gelsolin knock-down compared with the total loss of
secretion in C3 cells, but also the inability of C3 cells
transfected with HA-tagged gelsolin to recover their capacity
for regulated secretion. However, this latter result might also
be the consequence of a dysregulation of calcium homeostasis
resulting in the abnormal activation of gelsolin in C3 cells, as
suggested by the immunolocalisation of HA-tagged gelsolin
along extensively depolymerised actin filaments in basal
conditions in these cells (this only occurs after glucose
stimulation in B1 cells).
Gelsolin, which has previously been identified as being
expressed in a number of hormone-secreting tissues (Nelson
and Boyd, III, 1985), has been shown to affect the mobility of
chromaffin granules (Miyamoto et al., 1993) and synaptic
vesicles (Miyamoto, 1995) by disassembling actin filament
networks in vitro. These observations are consistent with a role
for gelsolin in coupling the Ca2+ signal elicited after glucose
stimulation (Lang, 1999) and the rearrangement of the actin
cytoskeleton at the onset of secretion. Scinderin, the closest
homologue to gelsolin, has been previously suggested to play
a role in -cell actin remodelling (Bruun et al., 2000), but the
very low to no expression of this protein outside a small
number of tissues, such as renal tubular and intestinal epithelial
cells, together with the differential pattern of gelsolin and
scinderin expression (Lueck et al., 1998) conflict with the
proposed model for scinderin function in insulin exocytosis
(Kwiatkowski, 1999).
The small GTPase Rac1 has recently been described as
playing a role in insulin secretion. Glucose exposure induces
Rac1 activation in the rat pancreatic INS cell line and
expression of a dominant-negative Rac1 mutant inhibits second
phase insulin secretion (Li et al., 2004). Gelsolin is known to
act as a downstream effector of Rac (Azuma et al., 1998). Active
Rac indirectly dissociates gelsolin-actin complexes (Arcaro,
1998), probably via its association with phosphatidylinositol
5-kinases. This association promotes the translocation of
phosphatidylinositol 5-kinases to the plasma membrane,
increasing the local concentration of phosphatidylinositol 4,5-
bisphosphate (Anderson et al., 1999), an inhibitor of gelsolin
severing activity (Sun et al., 1999). In pancreatic -cells,
gelsolin activation by Ca2+ could promote actin filament
severing resulting in the transient disruption of the actin
cytoskeleton during the first phase of insulin secretion. Gelsolin
could then be regulated by glucose-activated Rac1, inactivating
the actin-severing process, and triggering actin filament
uncapping and creation of new actin barbed ends. This would
promote rapid actin filament assembly required for membrane
ruffling and recruitment of granules to the plasma membrane
during the second phase of insulin secretion (Li et al., 1994).
Alternatively, gelsolin may affect insulin secretion in a totally
different manner, either by modulating stimulus-dependent ion
channel function (Furukawa et al., 1997), or by modulating lipid
signalling events via its interaction with phosphoinositides
(Kwiatkowski, 1999).
In the last part of this study we have explored the possibility
of the actin cytoskeleton playing a role in the propagation of
signalling events leading to insulin secretion in -cells. In
particular, we have investigated whether the state of actin
polymerisation in -cells has any effect on the glucose-induced
activation of the MAPK member ERK1/2. The MAPK
pathway has important roles in many cellular events, including
proliferation, differentiation, survival and secretion (Hunter,
1995). In -cells, glucose is known to activate ERK1/2 (Frodin
et al., 1995; Briaud et al., 2003), and a recent report has shown
that glucose-induced ERK1/2 activity remains in the cytoplasm
and participates in the regulation of insulin secretion in MIN6
cells (Longuet et al., 2005).
In this context, it is worth noting that, in contrast to what
has been found in the above-mentioned study (Longuet et al.,
2005), we could only establish a contribution of ERK1/2
during the first phase but not the second phase of insulin
secretion in B1 cells. The role of ERK1/2 in insulin secretion
therefore coincides temporally with the transient remodelling
of the actin cytoskeleton exerted by glucose in MIN6
(Thurmond et al., 2003) and MIN6 B1 cells. In addition, actin
disassembly by latrunculin B pre-treatment was found
to enhance the short-term glucose-induced ERK1/2
phosphorylation in both B1 and C3 cells. These results point
towards a link between glucose-induced transient actin
depolymerisation and the short-term transduction of signals
from glucose to the MAPK pathway in MIN6 cells.
Although nuclear translocation of ERK1/2 is required
for transcriptional changes, the cellular consequences of
cytoplasmic signalling have not yet been defined. The role of
ERK1/2 in the regulation of insulin secretion is most probably
exerted via the phosphorylation of specific targets, one of
which is the protein synapsin I (Longuet et al., 2005), known
to be associated with insulin granules (Matsumoto et al., 1999),
and proposed to be involved in granule translocation prior to
insulin exocytosis (Yamamoto et al., 2003). In adult synapses,
synapsin I tethers synaptic vesicles to the actin cytoskeleton
in a phosphorylation-dependent manner, regulating the
proportion of vesicles available for release (Jovanovic et al.,
1996). Our observation that activated phosphoERK1/2
accumulates at the tips of actin filaments adjacent to the plasma
membrane after 5 minutes of glucose stimulation indicates that
these are the main sites of action of phosphoERK1/2 for the
potentiation of insulin secretion. Membrane-proximal ERK1/2
localisation has been previously implicated in specific
processes such as the activation of M-calpain downstream of
epidermal growth factor receptor signalling (Glading et al.,
2001). In view of our own results, we propose a mechanism of
action in which ERK1/2 is activated specifically at the tips of
actin filaments in close contact with the plasma membrane after
glucose-dependent F-actin remodelling. This mechanism does
not preclude the previously reported role for a cAMP/PKA-
dependent pathway in the glucose-induced activation of
ERK1/2 (Briaud et al., 2003), but simply suggests that
remodelling of actin in response to glucose favours
accessibility of ERK1/2 to its specific activation sites.
Activated phosphoERK1/2 would subsequently phosphorylate
specific targets at these sites, such as synapsin I present in
insulin granules at the proximity of the plasma membrane,
facilitating the onset of secretion. 
In conclusion, we have established a relationship between
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the differing actin cytoskeleton polymerisation levels and
secretory properties of the B1 and C3 sublines and we have
demonstrated a role for the Ca2+-dependent actin remodelling
protein gelsolin in regulated insulin secretion. We have also
unveiled a connection between the state of actin polymerisation
and the transduction of signals through the MAPK pathway,
showing that actin remodelling in pancreatic -cells can have
functional repercussions that go beyond the removal of a
physical barrier for insulin granules to access the membrane.
Materials and Methods
Drugs and antibodies
Latrunculin B and the MEK1/2 inhibitor PD98059 were purchased from
Calbiochem (La Jolla, CA, USA). Latrunculin B was used at 10 M and PD98059
at 100 M final concentrations. Alexa Fluor 546-phalloidin was obtained from
Molecular Probes (Eugene, OR, USA). Primary antibodies were, mouse anti-pan
actin monoclonal antibody (mAb) from Chemicon International (Temecula, CA,
USA), rabbit anti-ERK1/2 polyclonal antibody (pAb) and rabbit anti-
phosphoERK1/2 pAb from Cell Signaling (Beverly, MA, USA), mouse anti-HA tag
mAb from Roche (Basel, Switzerland) and rabbit anti-gelsolin pAb (a gift from C.
Chaponnier, University of Geneva Medical School, Switzerland). Secondary
antibodies were: donkey anti-rabbit Alexa Fluor 555, goat anti-mouse Alexa Fluor
488 and donkey anti-rabbit Alexa Fluor 488 from Molecular Probes; donkey anti-
rabbit horseradish peroxidase (HRP) and sheep anti-mouse HRP from Amersham
Biosciences (Little Chalfont, UK).
Primary -cell purification
Islets of Langerhans were isolated by collagenase digestion of pancreas from adult
male C57BL/6 mice or Wistar rats followed by Ficoll purification based on a method
adapted from (Rouiller et al., 1990). Pancreatic -cells were separated from non--
cells by autofluorescence-activated sorting using the fluorescence-activated cell
sorter FACStar–Plus (BD Biosciences, NJ, USA) and used for western blot analysis
of gelsolin levels.
Cell lines and culture conditions
Both B1 and C3 cells were cultured in complete medium as described previously
(Lilla et al., 2003). In general, cells were subcultured into 35 mm wells up to passage
25 to ~80% confluency before the experiments. For confocal microscopy, cells were
plated, before fixation, onto 35-mm glass bottom microwell dishes (MatTek,
Ashland, MA, USA) coated with extracellular matrix from 804G rat bladder
carcinoma cells to favour cell attachment (Bosco et al., 2000).
Insulin secretion assays
Cells were washed twice with a modified Krebs-Ringer bicarbonate Hepes buffer
[KRBH: 125 mM NaCl, 4.74 mM KCl, 1 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM
MgSO4, 5 mM NaHCO3, 25 mM Hepes (pH 7.4), 0.1% BSA] and pre-incubated
with this same buffer containing the drug of interest or DMSO (as a control) for 2
hours at 37°C. Cells were then incubated for 1 hour at 37°C in KRBH with drugs
or DMSO (basal conditions), followed by 1 hour in KRBH supplemented with 10
or 20 mM glucose (stimulated conditions). For time-course analysis of insulin
secretion, cells were pre-incubated as above and incubated in stimulated conditions
for the different time points analysed. Basal and stimulated incubation buffers were
recovered, and cells were extracted with acid-ethanol. The amount of insulin in the
incubation buffers and cell extracts was measured by radioimmunoassay (RIA) as
described previously (Lilla et al., 2003; Herbert et al., 1965). Insulin secretion is
expressed as a percentage of the total insulin content, which is the sum of insulin
contained in basal and stimulated buffers and in cell extracts.
Real-time reverse-transcription (RT)-PCR
Total RNA was extracted with the RNeasy Mini Kit (Qiagen, Germany) following
the manufacturer’s instructions, and used for cDNA synthesis with Superscript II
(Invitrogen, Carlsbad, CA, USA). Primers were designed using the Primer Express
software, and real-time RT-PCR was performed using the qPCR core kit for SYBR
Green I (Eurogentec, Belgium) in the ABI PRISM 7000 Sequence Detection System
(PE Applied Biosystems, CA, USA). Actin was used as a control for data
normalisation. 
RNA interference (RNAi)-mediated silencing of endogenous
gelsolin
Two 64 base pair (bp) sequences encoding two different 21-bp-long small hairpin
RNAs (shRNAs) specific for mouse gelsolin were cloned into both pSUPER and
pSUPER-GFP plasmids (from OligoEngine, Inc., Seattle, WA, USA). A similar
sequence encoding a non-specific shRNA without mammalian homology was also
cloned and used as a negative control. Both shRNAs were tested for their capacity
to knock-down gelsolin in B1 cells as follows. Cells were transiently transfected
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with the pSUPER-GFP plasmid containing either one of the shRNAs against
gelsolin or the negative control shRNA. Cells were cultured for 72 hours for RNAi
expression before selection of GFP-positive cells by fluorescence-activated cell
sorting (FACS). Selected cells were pooled and lysed for western blot analysis of
gelsolin levels compared to negative control cells. The shRNA sequence 5-
AAAGGAGGTGTGGCATCTGGA-3 exhibited a greater silencing capacity and
was employed in all subsequent experiments. 
Transient transfection of cells
Cells were transfected with the different plasmids using LipofectamineTM 2000
reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s instructions.
Transfected cells were incubated for 72 hours to allow for RNAi expression.
Growth hormone secretion assays
To study secretion specifically from transfected cells, the cells were co-transfected
with a human growth hormone (hGH)-expressing vector and the vector of interest
(1:3 DNA ratio), and incubated for 72 hours before analysis of hGH secretion (used
as a surrogate marker for insulin secretion from transfected cells).
Co-transfected cells were washed twice in KRBH supplemented with 2.8 mM
glucose and pre-incubated with this same buffer for 2 hours at 37°C. Cells were
then incubated for 1 hour at 37°C in KRBH with 2.8 mM glucose, followed by 1
hour incubation with KRBH supplemented with 16.7 mM glucose or 16.7 mM
glucose + 1 mM of 3-isobutyl-1-methylxanthine (IBMX) (stimulated conditions).
Basal and stimulated incubation buffers were recovered, and cells were extracted
with acid-ethanol. The amount of growth hormone in the incubation buffers and cell
extracts was measured by ELISA using the hGH ELISA kit from Roche Diagnostics
(Basel, Switzerland), following the manufacturer’s instructions. Growth hormone
secretion is expressed as a percentage of the total growth hormone content, which
is the sum of growth hormone contained in the basal and stimulated buffers and cell
extracts.
Immunofluorescence and confocal microscopy
Cells were washed in PBS, fixed/permeabilised on ice for 30 minutes in fixation
solution (2% paraformaldehyde + 0.1% Triton X-100 in PBS), washed four times
in PBS and blocked for 15 minutes with 1% BSA. Fixed cells were incubated in a
moist chamber with primary antibody in 1% BSA for 1 hour, followed by four
washes of 5-10 minutes each in PBS before incubation with the secondary antibody
in 1% BSA for a further hour. For actin labelling, cells were incubated with Alexa
Fluor 546-phalloidin for 20 minutes after fixation. Nuclei were detected with the
DNA-binding dye DRAQ5TM (Biostatus Ltd., UK). Cell samples were observed
under a Zeiss LSM 510 inverted confocal microscope using a 63 oil immersion
lens. Images were acquired and processed using the Lsm510 software (Carl Zeiss
AG, Germany).
SDS-PAGE and western blotting
Cultured cells were washed in PBS and solubilised in lysis buffer (20 mM Tris-HCl,
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP-40) supplemented with
Complete Mini protease inhibitor cocktail (Roche, Switzerland). Lysates were pre-
cleared at 16,000 g for 5 minutes at 4°C, and total protein levels were quantified
with the DC protein assay kit (BioRad, Hercules, CA, USA). Protein samples were
re-suspended in SDS-PAGE sample buffer, boiled for 5 minutes, and resolved by
SDS-polyacrylamide gel electrophoresis on discontinuous mini-gels. Proteins were
then electroblotted for 45 minutes onto a Protran nitrocellulose Transfer Membrane
(Schleicher & Schuell GmbH, Germany). Membranes were treated with blocking
solution [5% skimmed milk in TBS-Tween (TBS + 0.05% Tween 20)] for 1 hour
at room temperature and incubated for 16 hours at 4°C with primary antibody in
blocking solution (or TBS-Tween + 5% BSA for anti-phosphoERK1/2 pAb).
Following three TBS-Tween washes, membranes were incubated with secondary
antibody for 90 minutes, also in blocking solution. After three more TBS-Tween
washes, blots were incubated with the ECL Plus Western Blotting detection system
(Amersham Biosciences, UK) and exposed to BioMax MR Films (Kodak,
Rochester, NY, USA). The films were developed in a Kodak M35 X-OMAT
Processor, and scanned. Scan band density was determined with Scion Image for
Windows. 
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